San Francisco, CA and London, England (PRWEB) November 12, 2013
Healthline and TrialReach have teamed up to offer a new way to connect patients with clinical trials in the U.S., lowering the cost and time associated with developing, testing and bringing to market promising new treatments. Healthline properties have been growing rapidly in 2013 -- 168 percent since January, according to comScore -- which means Healthline is uniquely capable of delivering this important new service to a very large U.S. audience.
Like Healthline, TrialReach makes complicated health information easy to digest for the average person by converting “medical speak” into understandable, interactive Web-based multimedia content. Using a simple form on Healthline.com, patients can immediately determine if they are eligible for a trial through easy-to-use pre-screeners.
TrialReach is already making an impact on the lives of people like Orange County, California resident Kristen Lane, 49, who was diagnosed with Lupus five years ago when she was a single mother. Now married, after exhausting all other treatment options she is currently enrolled in a clinical trial that has significantly improved her health and well-being.
“I feel 70 percent better than I did,” said Lane. “It is easier to do my job, go to the gym and walk my dog. I just feel better. And I found the trial I’m on using TrialReach.”
One of the biggest challenges in clinical research is finding patients. It is estimated that 80 percent of all trials miss deadlines, causing losses of up to $8 million per drug per day and slowing the time-to-market for new treatments. The challenge is even greater for smaller independent medical research teams who have limited resources to promote their trials and find the patients they need.
“Healthline partners with many of the top health information sites in the United States, anchored by Healthline.com and including Yahoo! Health, Drugs.com and many others,” said David Kopp, EVP and GM of Healthline Media. “Our ability to reach a huge and growing audience is unique, which means we’re able to bring TrialReach to millions of people who could potentially benefit from this important service.”
TrialReach also enables medical researchers to reach a large number of potential new patients in just a few clicks. Unlike other initiatives, TrialReach is open and virtually free to all research teams, including smaller biotech firms and academic institutions. By reducing the barrier of entry for all researchers, TrialReach and Healthline hope to help transform the entire sector, exposing many more treatments in development to patients in a useful and reliable manner.
“We built TrialReach from a real desire to significantly improve the way clinical research is conducted around the world,” said founder and CEO Pablo Graiver. “By leveraging the scale and power of the Internet to empower patients to take more control over their own healthcare destinies and to give researchers highly efficient, cost-effective ways to reach appropriate candidates for their trials, we can literally change lives for the better.”
San Francisco-based Healthline is a leading provider of intelligent health information and technology solutions, enabling providers and everyday people to make more confident, informed healthcare decisions. The company's proprietary health taxonomy platform powers a suite of marketing, health search, data-mining and content solutions for global enterprises and advertisers. Healthline is a Deloitte Technology Fast 500 company for the last four years. For more company information, visit corp.healthline.com.
TrialReach.com has created a global internet platform to make clinical trials easier for patients to find, understand and apply for. The ultimate goal of the company is to make new treatments available more quickly and efficiently. TrialReach was launched in 2010 and is based in London, UK.
Kristen Lane is one of the thousands of patients who has already used TrialReach to apply for a clinical trial. For more on Kristen Lane’s story, see the video: Kristen’s Story.
# # #